Tasquinimod effect on warfarin pharmacodynamics and pharmacokinetics in healthy volunteers

Phase 1, open-label, single-arm trial of tasquinimod and warfarin in prostate cancer (PCa), sponsored by Active Biotech AB. Primary endpoints: Area under the INR effect curve from 0 to 144 hours, Baseline-corrected area under the INR effect curve from 0 to 144 hours and 2 more. Started Nov 2011; status: active, not recruiting.